Literature DB >> 12497643

Splice mutations in the p53 gene: case report and review of the literature.

R Holmila1, C Fouquet, J Cadranel, G Zalcman, T Soussi.   

Abstract

Splice mutations in the p53 gene (TP53) are described as rare events that occur at a frequency of less than 1%. Using a functional assay based on the transcriptional activity of p53 and using RNA as starting material, we describe here a p53 splice mutation that could not be detected by genomic sequencing. This lack of detection is due to a deletion of the region complementary to primers commonly used for amplification. Reviewing the literature, we show that p53 splice mutations have been certainly underestimated and that careful strategy should be used for a complete mutational analysis of the p53 gene. Furthermore, some p53 gene mutations described as "neutral" due to the absence of any amino-acid change are truly deleterious, as they affect gene splicing. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12497643     DOI: 10.1002/humu.9104

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  17 in total

1.  Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines.

Authors:  Annemarie Koch; Jiri Hatina; Harald Rieder; Hans-Helge Seifert; Wolfgang Huckenbeck; Frank Jankowiak; Andrea R Florl; Robert Stoehr; Wolfgang A Schulz
Journal:  Cell Oncol (Dordr)       Date:  2012-06-06       Impact factor: 6.730

2.  Structural genomics analysis of alternative splicing and application to isoform structure modeling.

Authors:  Peng Wang; Bo Yan; Jun-Tao Guo; Chindo Hicks; Ying Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-14       Impact factor: 11.205

3.  Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.

Authors:  Xiao-mo Wu; Jing-geng Fu; Wang-zhong Ge; Jiang-yan Zhu; Jun-yong Wang; Wei Zhang; Wei Qian; Ke-ke Huo
Journal:  J Zhejiang Univ Sci B       Date:  2007-02       Impact factor: 3.066

4.  Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance.

Authors:  Peter S Choi; Yulin Li; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-28       Impact factor: 11.205

5.  Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene.

Authors:  Flora Doffe; Vincent Carbonnier; Manon Tissier; Bernard Leroy; Isabelle Martins; Johanna S M Mattsson; Patrick Micke; Sarka Pavlova; Sarka Pospisilova; Jana Smardova; Andreas C Joerger; Klas G Wiman; Guido Kroemer; Thierry Soussi
Journal:  Cell Death Differ       Date:  2020-11-30       Impact factor: 15.828

6.  Sequence-dependent cooperative binding of p53 to DNA targets and its relationship to the structural properties of the DNA targets.

Authors:  Itai Beno; Karin Rosenthal; Michael Levitine; Lihi Shaulov; Tali E Haran
Journal:  Nucleic Acids Res       Date:  2010-11-10       Impact factor: 16.971

7.  Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma.

Authors:  S Gad; S H Lefèvre; S K Khoo; S Giraud; A Vieillefond; V Vasiliu; S Ferlicot; V Molinié; Y Denoux; N Thiounn; Y Chrétien; A Méjean; M Zerbib; G Benoît; J M Hervé; G Allègre; B Bressac-de Paillerets; B T Teh; S Richard
Journal:  Br J Cancer       Date:  2006-11-28       Impact factor: 7.640

Review 8.  Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment.

Authors:  Roman Hrstka; Philip J Coates; Borivoj Vojtesek
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

9.  TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.

Authors:  Pavla Brachova; Samuel R Mueting; Matthew J Carlson; Michael J Goodheart; Anna M Button; Sarah L Mott; Donghai Dai; Kristina W Thiel; Eric J Devor; Kimberly K Leslie
Journal:  Int J Oncol       Date:  2014-11-11       Impact factor: 5.650

Review 10.  The consequence of oncomorphic TP53 mutations in ovarian cancer.

Authors:  Pavla Brachova; Kristina W Thiel; Kimberly K Leslie
Journal:  Int J Mol Sci       Date:  2013-09-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.